A podcast episode featuring Dr. Aaron Zelikovich explores the growing debate over whether combining two disease-modifying treatments could improve outcomes for patients with spinal muscular atrophy. The neuromuscular specialist at Lenox Hill Hospital discusses what evidence currently supports dual therapy approaches and why significant questions remain unanswered.
Limited Evidence Shapes Clinical Debate
Dr. Zelikovich acknowledges that while interest in combination treatment has increased among clinicians and families, the data backing dual therapy remains sparse. He emphasizes that most available evidence comes from small studies and real-world observations rather than rigorous clinical trials designed to test whether adding a second therapy actually produces better results.
Gene replacement therapy targeting the SMN gene has transformed survival and motor development in infants and children with SMA since its approval. However, some patients do not achieve expected milestones even after treatment. This gap has fueled discussions about whether a second SMN-targeted medication could help those still struggling with residual weakness or progressive decline.
Related: Neurology and Headache Societies Release New Migraine Guideline
Insurance and Access Create Additional Barriers
Beyond the scientific uncertainties, clinicians face practical obstacles when considering combination approaches. Insurance companies often deny coverage for adding a second therapy when evidence supporting its necessity is limited. These access challenges mean that even physicians who believe dual treatment might benefit certain patients may be unable to prescribe it without extensive appeals processes.
The conversation highlights how families frequently arrive at clinic appointments having already researched combination therapies online, sometimes from patient communities sharing anecdotal success stories. Zelikovich describes the difficulty of managing expectations when early enthusiasm from one family conflicts with the broader clinical evidence showing mixed results across different patient populations.
Biomarkers Needed to Guide Treatment Decisions
One central theme throughout the discussion involves the absence of reliable markers that could predict which patients might benefit from additional therapy. Without clear biomarkers indicating treatment response or disease progression, clinicians lack objective tools to determine who genuinely needs a second medication versus those stable on current regimens.
Researchers have begun exploring various candidates, including neurofilament light chain levels and other blood-based indicators of motor neuron health. However, Dr. Zelikovich notes that none have yet demonstrated sufficient sensitivity and specificity to guide individual treatment decisions in routine clinical practice.
Related: New Guidelines for Stroke Rehabilitation Released
Adult SMA Population Presents New Questions
The natural history of SMA in adults has shifted dramatically since disease-modifying treatments became available. Many patients who survived into adolescence and adulthood thanks to early intervention now face different clinical challenges than those described in historical literature written before these therapies existed.
Adults who received gene therapy years ago may be experiencing gradual changes that raise questions about long-term efficacy. Some clinicians wonder whether these individuals might benefit from supplemental treatment, but the evidence to support such decisions remains thin. Prospective studies tracking adult patients over extended periods would help clarify whether combination approaches offer meaningful advantages for this growing population.
For now, the medical community awaits results from ongoing research initiatives designed to generate stronger evidence about dual therapy safety and effectiveness. Until then, clinicians like Zelikovich continue handling conversations with families who want definitive answers about whether combining treatments could help their loved ones. The path forward almost certainly requires coordinated efforts between academic medical centers, patient advocacy groups, and regulatory agencies willing to support the large-scale studies necessary to resolve these uncertainties.